File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Outcome of long-term treatment with mycophenolate mofetil in patients with severe lupus nephritis

TitleOutcome of long-term treatment with mycophenolate mofetil in patients with severe lupus nephritis
Authors
KeywordsMedical sciences
Urology and nephrology
Issue Date2012
PublisherAmerican Society of Nephrology. The Journal's web site is located at http://www.jasn.org
Citation
The 45th Annual Meeting of the American Society of Nephrology (Kidney Week 2012), San Diego, CA., 30 October-4 November 4 2012. In Journal of the American Society of Nephrology, 2012, v. 23 abstract suppl., p. 714A, abstract SA-PO337 How to Cite?
AbstractBACKGROUND: Corticosteroids with mycophenolate mofetil (MMF) has proven efficacy when used as induction or maintenance immunosuppression for proliferative lupus nephritis, but data on long-term mycophenolate mofetil treatment is lacking. METHODS: This was a single-centre retrospective study of patients with Class III/IV±V lupus nephritis who have received prednisolone and MMF continuously as treatment in the early phase and the long-term maintenance phase. RESULTS: 65 patientswere included. 31 patients were treated with only prednisolone and MMF throughout (Group I). 23 patients had their MMF substituted with azathioprine (AZA)(Group II) and 11 patients with calcineurin inhibitors (CNI)(Group III) at some point during the maintenance phase. The follow-up was 91.9±47.7 months. The 10-year patient and renal survival rates were 91% and 86% respectively, with no difference between the three groups. Relapse-free survival was higher in Group I than Group II and Group III (76% vs 56% vs 43% respectively at 5-year; 69% vs 32% vs 0% respectively at 10-year; I vs II, p=0.049; I vs III, p=0.019; II vs III, p=0.490). Patients who received MMF for more than 24 months showed better relapse-free survival than those treated for shorter durations (88% vs 48% respectively at 5-year; 81% vs 28% respectively at 10-year; p<0.001). Serum creatinine was lower in Group I at 10 years. Apart from more anemia with MMF treatment, the side-effects profile was similar in patients during MMF, AZA, or CNI treatment. CONCLUSIONS: Continuous treatment with corticosteroids and MMF as both induction and long-term maintenance immunosuppression is associated with favorable long-term outcome and possibly a lower risk of disease flare compared with other maintenance immunosuppressive medications.
DescriptionSaturday Poster - Clinical Glomerular and Tubulointerstitial Disorders 2: abstract SA-PO337
Persistent Identifierhttp://hdl.handle.net/10722/185008
ISSN
2015 Impact Factor: 8.491
2015 SCImago Journal Rankings: 4.699

 

DC FieldValueLanguage
dc.contributor.authorYap, DYHen_US
dc.contributor.authorMa, MKMen_US
dc.contributor.authorChan, DTMen_US
dc.date.accessioned2013-07-15T10:23:48Z-
dc.date.available2013-07-15T10:23:48Z-
dc.date.issued2012en_US
dc.identifier.citationThe 45th Annual Meeting of the American Society of Nephrology (Kidney Week 2012), San Diego, CA., 30 October-4 November 4 2012. In Journal of the American Society of Nephrology, 2012, v. 23 abstract suppl., p. 714A, abstract SA-PO337en_US
dc.identifier.issn1046-6673-
dc.identifier.urihttp://hdl.handle.net/10722/185008-
dc.descriptionSaturday Poster - Clinical Glomerular and Tubulointerstitial Disorders 2: abstract SA-PO337-
dc.description.abstractBACKGROUND: Corticosteroids with mycophenolate mofetil (MMF) has proven efficacy when used as induction or maintenance immunosuppression for proliferative lupus nephritis, but data on long-term mycophenolate mofetil treatment is lacking. METHODS: This was a single-centre retrospective study of patients with Class III/IV±V lupus nephritis who have received prednisolone and MMF continuously as treatment in the early phase and the long-term maintenance phase. RESULTS: 65 patientswere included. 31 patients were treated with only prednisolone and MMF throughout (Group I). 23 patients had their MMF substituted with azathioprine (AZA)(Group II) and 11 patients with calcineurin inhibitors (CNI)(Group III) at some point during the maintenance phase. The follow-up was 91.9±47.7 months. The 10-year patient and renal survival rates were 91% and 86% respectively, with no difference between the three groups. Relapse-free survival was higher in Group I than Group II and Group III (76% vs 56% vs 43% respectively at 5-year; 69% vs 32% vs 0% respectively at 10-year; I vs II, p=0.049; I vs III, p=0.019; II vs III, p=0.490). Patients who received MMF for more than 24 months showed better relapse-free survival than those treated for shorter durations (88% vs 48% respectively at 5-year; 81% vs 28% respectively at 10-year; p<0.001). Serum creatinine was lower in Group I at 10 years. Apart from more anemia with MMF treatment, the side-effects profile was similar in patients during MMF, AZA, or CNI treatment. CONCLUSIONS: Continuous treatment with corticosteroids and MMF as both induction and long-term maintenance immunosuppression is associated with favorable long-term outcome and possibly a lower risk of disease flare compared with other maintenance immunosuppressive medications.-
dc.languageengen_US
dc.publisherAmerican Society of Nephrology. The Journal's web site is located at http://www.jasn.org-
dc.relation.ispartofJournal of the American Society of Nephrologyen_US
dc.relation.ispartofKidney Week 2012-
dc.subjectMedical sciences-
dc.subjectUrology and nephrology-
dc.titleOutcome of long-term treatment with mycophenolate mofetil in patients with severe lupus nephritisen_US
dc.typeConference_Paperen_US
dc.identifier.emailYap, DYH: desmondy@hku.hken_US
dc.identifier.emailChan, DTM: dtmchan@hku.hken_US
dc.identifier.authorityYap, DYH=rp01607en_US
dc.identifier.authorityChan, DTM=rp00394en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros215595en_US
dc.identifier.volume23-
dc.identifier.issueabstract suppl.-
dc.identifier.spage714A, abstract SA-PO337-
dc.identifier.epage714A, abstract SA-PO337-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats